Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jitesh Patel

Colon & Rectal Surgery Lexington, KY Medical Doctor

NPI 1265522601 CMS profile 656075

800 Rose St, Lexington, KY 40536

Open in the dashboard

General payments

$12,376

39 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jitesh Patel of Lexington, KY is reported in the CMS Open Payments database as having received $12,376 across 39 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Colon & Rectal Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,497 5
2024 General $9,950 20
2023 General $92 2
2022 General $410 5
2021 General $89 4
2020 General $241 2
2019 General $98 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jitesh Patel
  • Colon & Rectal Surgery median
  • Middle half of Colon & Rectal Surgery
  • National median

In program year 2025, general payments to Jitesh Patel were reported at $1,497. Among 1,481 Colon & Rectal Surgery profiles paid that year, the median was $317 and the middle half received between $109 and $1,248.

Show as a table
Year Jitesh Patel Colon & Rectal Surgery median Middle half National median
2019 $98 $443 $125–$2,179 $163
2020 $241 $167 $53–$931 $114
2021 $89 $207 $72–$1,272 $132
2022 $410 $341 $111–$1,587 $149
2023 $92 $322 $115–$1,420 $160
2024 $9,950 $328 $112–$1,354 $164
2025 $1,497 $317 $109–$1,248 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $9,644 16 payments
  2. Histosonics, Inc. $1,141 1 payment
  3. Medtronic, Inc. $634 8 payments
  4. Ethicon US, LLC $258 4 payments
  5. Axonics Modulation Technologies, Inc. $180 2 payments
  6. Baxter Healthcare $124 1 payment
  7. Covidien LP $117 1 payment
  8. Integra LifeSciences Corporation $104 2 payments
  9. Olympus America Inc. $98 1 payment
  10. Applied Medical Resources Corporation $36 1 payment
  11. Other $41 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $8,500 5 payments
  2. Travel and Lodging $2,030 4 payments
  3. Food and Beverage $1,846 30 payments
Products named General payments · program years 2019–2025
  1. DAVINCI XI $8,500 5 payments
  2. Da Vinci Surgical System $1,144 11 payments
  3. Signia $329 3 payments
  4. Echelon Flex $231 3 payments
  5. Axonics $180 2 payments
  6. TISSEEL $124 1 payment
  7. INTERSTIM $122 1 payment
  8. LigaSure $117 1 payment
  9. EEA $110 1 payment
  10. Integra $104 2 payments
  11. Other $581 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

324

Median for General Surgery: 59

Drug cost

$14,435

Median for General Surgery: $393

Branded share of claims

33%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 29 $11,821
Loperamide Loperamide Hcl Brand 24 $744
Neomycin Sulfate Generic 73 $466
Scopolamine Generic 22 $329
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 21 $308
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 18 $252
Metronidazole Generic 78 $176
Ondansetron Odt Ondansetron Brand 15 $142
Methocarbamol Generic 24 $130
Oxycodone Hcl Generic 20 $69

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$117,424

Medicare's payments for the services billed

Medicare patients

154

Average age 68

Services billed

446

80 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 51%
Arthritis 45%
Depression 37%
Diabetes 35%
Ischemic heart disease 31%
Chronic kidney disease 31%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Colon & Rectal Surgery in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record